360 related articles for article (PubMed ID: 22563432)
41. Inactivation of peroxisome proliferator-activated receptor isoforms alpha, beta/delta, and gamma mediate distinct facets of hypertrophic transformation of adult cardiac myocytes.
Pellieux C; Montessuit C; Papageorgiou I; Lerch R
Pflugers Arch; 2007 Dec; 455(3):443-54. PubMed ID: 17643263
[TBL] [Abstract][Full Text] [Related]
42. Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans.
Blednov YA; Benavidez JM; Black M; Ferguson LB; Schoenhard GL; Goate AM; Edenberg HJ; Wetherill L; Hesselbrock V; Foroud T; Harris RA
Alcohol Clin Exp Res; 2015 Jan; 39(1):136-45. PubMed ID: 25516156
[TBL] [Abstract][Full Text] [Related]
43. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
Jeong HW; Lee JW; Kim WS; Choe SS; Kim KH; Park HS; Shin HJ; Lee GY; Shin D; Lee H; Lee JH; Choi EB; Lee HK; Chung H; Park SB; Park KS; Kim HS; Ro S; Kim JB
Diabetes; 2011 Feb; 60(2):496-506. PubMed ID: 21270261
[TBL] [Abstract][Full Text] [Related]
44. Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor.
Tao H; Aakula S; Abumrad NN; Hajri T
Am J Physiol Endocrinol Metab; 2010 Jan; 298(1):E68-79. PubMed ID: 19861583
[TBL] [Abstract][Full Text] [Related]
45. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
Srivastava RA
Eur J Pharmacol; 2009 Apr; 607(1-3):258-63. PubMed ID: 19245804
[TBL] [Abstract][Full Text] [Related]
46. Cultured human periosteal-derived cells have inducible adipogenic activity and can also differentiate into osteoblasts in a perioxisome proliferator-activated receptor-mediated fashion.
Hah YS; Joo HH; Kang YH; Park BW; Hwang SC; Kim JW; Sung IY; Rho GJ; Woo DK; Byun JH
Int J Med Sci; 2014; 11(11):1116-28. PubMed ID: 25170294
[TBL] [Abstract][Full Text] [Related]
47. Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α.
Takano M; Otsuka F; Matsumoto Y; Inagaki K; Takeda M; Nakamura E; Tsukamoto N; Miyoshi T; Sada KE; Makino H
Mol Cell Endocrinol; 2012 Jan; 348(1):224-32. PubMed ID: 21888945
[TBL] [Abstract][Full Text] [Related]
48. Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.
Ciudin A; Hernandez C; Simó R
Curr Top Med Chem; 2012; 12(6):585-604. PubMed ID: 22242856
[TBL] [Abstract][Full Text] [Related]
49. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
[TBL] [Abstract][Full Text] [Related]
50. Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding.
Wierzbicki M; Chabowski A; Zendzian-Piotrowska M; Harasim E; Górski J
Adv Med Sci; 2009; 54(1):59-65. PubMed ID: 19403437
[TBL] [Abstract][Full Text] [Related]
51. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and -independent mechanisms.
Mezei O; Li Y; Mullen E; Ross-Viola JS; Shay NF
Physiol Genomics; 2006 Jun; 26(1):8-14. PubMed ID: 16507786
[TBL] [Abstract][Full Text] [Related]
52. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Srivastava RA
Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
[TBL] [Abstract][Full Text] [Related]
54. Peroxisome proliferator-activated receptors-α and -γ, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue.
Rosell M; Hondares E; Iwamoto S; Gonzalez FJ; Wabitsch M; Staels B; Olmos Y; Monsalve M; Giralt M; Iglesias R; Villarroya F
Endocrinology; 2012 Mar; 153(3):1162-73. PubMed ID: 22253419
[TBL] [Abstract][Full Text] [Related]
55. PPARs as therapeutic targets in cardiovascular disease.
van Bilsen M; van Nieuwenhoven FA
Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
[TBL] [Abstract][Full Text] [Related]
56. Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition.
Tian S; Wang R; Chen S; He J; Zheng W; Li Y
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641558
[TBL] [Abstract][Full Text] [Related]
57. Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.
Ye P; Fang H; Zhou X; He YL; Liu YX
Chin Med Sci J; 2004 Dec; 19(4):243-7. PubMed ID: 15669179
[TBL] [Abstract][Full Text] [Related]
58. Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis.
D'Argenio G; Petillo O; Margarucci S; Torpedine A; Calarco A; Koverech A; Boccia A; Paolella G; Peluso G
J Biol Chem; 2010 Aug; 285(35):27078-27087. PubMed ID: 20558736
[TBL] [Abstract][Full Text] [Related]
59. [Development of a cell-based peroxisome proliferator-activated receptors (PPARs) screening model and its application for evaluation of triterpenoids isolate from Alismatis Rhizoma].
Li XY; Wang XH; Huang XQ; Wu TT; Xu W; Wu SS
Zhongguo Zhong Yao Za Zhi; 2016 Nov; 41(21):4015-4022. PubMed ID: 28929690
[TBL] [Abstract][Full Text] [Related]
60. Astragalus polysaccharides repress myocardial lipotoxicity in a PPARalpha-dependent manner in vitro and in vivo in mice.
Chen W; Lai Y; Wang L; Xia Y; Chen W; Zhao X; Yu M; Li Y; Zhang Y; Ye H
J Diabetes Complications; 2015 Mar; 29(2):164-75. PubMed ID: 25499591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
